Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29144297 | 0.86 | NOTUM (0.51) | HCRTR1HCRTR2ABHD6ESR1ESR2 | |
| SCHEMBL19643004 | 0.84 | ESR1 (0.58) | HCRTR1HCRTR2ABHD6ESR1ESR2 | |
| SCHEMBL23327090 | 0.83 | CA1 (0.45) | ESR1ESR2CA1CA2CA7 | |
| SCHEMBL19951726 | 0.82 | HCRTR1 (0.45) | HCRTR1HCRTR2ABHD6ESR1ESR2 | |
| SCHEMBL29144304 | 0.82 | HPGDS (0.44) | HCRTR1HCRTR2MAPTNPC1RAB9A | |
| SCHEMBL28682598 | 0.81 | CA1 (0.41) | ABHD6ESR1ESR2CA1CA2 | |
| SCHEMBL28533143 | 0.81 | ESR1 (0.38) | ESR1ESR2CA1CA2CA7 | |
| SCHEMBL28535324 | 0.81 | ESR1 (0.38) | ESR1ESR2CA1CA2CA7 | |
| SCHEMBL19951725 | 0.81 | KMT2A (0.37) | HCRTR1HCRTR2ABHD6ESR1ESR2 | |
| SCHEMBL22466075 | 0.80 | MAP3K5 (0.45) | HCRTR1HCRTR2ABHD6KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017850-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114258392-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021032935-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032938-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218051-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2013-09-19 | — | — | US | disclosed |
| US-8436008-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HCRTR1 47/4885HCRTR2 55/4885ABHD6 4091/4885 |
| US-20130244999-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HCRTR1 47/4885HCRTR2 55/4885ABHD6 4091/4885 |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | HCRTR1 2653/4885HCRTR2 2894/4885ABHD6 1373/4885 |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | HCRTR1 2653/4885HCRTR2 2894/4885ABHD6 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.